The Impact of the Age, Dyspnoea, and Airflow Obstruction (ADO) Index on the Medical Burden of Chronic Obstructive Pulmonary Disease (COPD)

Li, Chin-Ling; Ma, Lin; Tsai, Yuh-Chyn; Tseng, Chun-Chieh; Chang, Chia‐Ling; Shen, Lien-Shi; Kuo, Ho‐Chang; Liu, Shih-Feng

doi:10.3390/jcm11071893

Cited by 5 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of COPD according to the FR definition increased from 4.37 to 24.03% in people in the age group 40-49 years and those aged 70 years and over, respectively, and increased from 5.22 to 14.23% according to the LLN definition among the same age group, respectively. Indeed, age is an important risk factor that increases COPD morbidity and the risk of exacerbations in affected individuals [88,89]. The model of Fletcher and Peto suggests that the rate of mean expiratory volume in one second (FEV1) decreases with age [90].…”

Section: Discussionmentioning

confidence: 99%

Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis

AL Wachami,

Guennouni,

Iderdar

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is a major public health problem. The present study aims to provide a global and regional estimate of the prevalence of COPD based on spirometry according to the two most widely used diagnostic criteria of COPD: fixed ratio (FR) and lower limit of normal (LLN). Methods We conducted a systematic review of the literature according to PRISMA guidelines. MEDLINE, Web of Sciences, and Scopus databases were searched to identify studies on the spirometry-based prevalence of COPD in individuals aged 40 years and older. The meta-analysis was performed using MedCalc 19 software. Results In total, 42 of the 3393 studies reviewed were eligible for inclusion. The overall prevalence of COPD in people aged 40 years and older was 12.64% (95% CI 10.75%-14.65%) and 7.38% (95% CI 5.47% − 9.55%) based on FR and LLN criteria, respectively. By gender, men had a higher prevalence of COPD compared to women (15.47%; 95% CI 12.22%-19.02% for men versus 8.79%; 95% CI 6.94%-10.82% for women). Using the LLN criteria, the prevalence of COPD in both sexes was almost identical (8.67%; 95% CI 8.44%- 8.90% for men and 8.00%; 95% CI 6.42% − 9.73% for women). We reported a high prevalence of COPD among smokers and the elderly by both definitions of airway obstruction. Regional prevalence estimates using the FR definition indicate that the highest COPD prevalence was recorded in the Americas and the lowest was recorded in the Eastern Mediterranean region. Using the LLN definition, the highest prevalence was recorded in the Southeast Asian region and the lowest prevalence was recorded in the American region. The most common COPD stage was stage II, with a prevalence of 50.46%. The results indicate a huge lack of prevalence data in the African and Eastern Mediterranean region. The results were given using a random-effect model due to the high heterogeneity between studies. Conclusion Results show that the prevalence of COPD differs according to the diagnostic criteria used. In addition, management and prevention strategies targeting risk factors for COPD are certainly needed to reduce the global burden of this chronic respiratory disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis

AL Wachami,

Guennouni,

Iderdar

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…Most BODE index studies have focused on predicting the exacerbation and mortality of COPD [ 26 ], and most ADO index studies have focused on exploring the effectiveness of prognosis evaluations [ 27 ]. Several studies have highlighted that the BODE and ADO index scores are associated with hospitalization rate and medical costs [ 16 , 17 , 22 ]. To date, no study has used the BODE and ADO indices to predict medical costs.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the ability to predict COPD severity, acute exacerbation, and mortality risk, the BODE and ADO indices may also be used to predict medical costs. At present, few studies have used the BODE or ADO indices to predict COPD-related medical costs [ 17 , 22 ]. Numerous chronic diseases entail considerable medical costs.…”

Section: Introductionmentioning

confidence: 99%

Comparison of BODE and ADO Indices in Predicting COPD-Related Medical Costs

Chang

Tseng

et al. 2023

Medicina

Self Cite

View full text Add to dashboard Cite

Background and Objectives:The ADO (age, dyspnea, and airflow obstruction) and BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) indices are often used to evaluate the prognoses for chronic obstructive pulmonary disease(COPD); however, an index suitable for predicting medical costs has yet to be developed. Materials and Methods: We investigated the BODE and ADO indices to predict medical costs and compare their predictive power. A total of 396 patients with COPD were retrospectively enrolled. Results: For hospitalization frequencies, BODE was R2 = 0.093 (p < 0.001), and ADO was R2 = 0.065 (p < 0.001); for hospitalization days, BODE was R2 = 0.128 (p < 0.001), and ADO was R2 = 0.071 (p < 0.001); for hospitalization expenses, BODE was R2 = 0.020 (p = 0.047), and ADO was R2 = 0.012 (p = 0.179). BODE and ADO did not differ significantly in the numbers of outpatient visits (BODE, R2 = 0.012, p = 0.179; ADO, R2 = 0.017, p = 0.082); outpatient medical expenses (BODE, R2 = 0.012, p = 0.208; ADO, R2 = 0.008, p = 0.364); and total medical costs (BODE, R2 = 0.018, p = 0.072; ADO, R2 = 0.016, p = 0.098). In conclusion, BODE and ADO indices were correlated with hospitalization frequency and hospitalization days. However, the BODE index exhibits slightly better predictive accuracy than the ADO index in these items.

show abstract

“…third leading cause of death worldwide and, according to the World Health Organization, ranks seventh among the top global causes of disability-adjusted life years [1,7]. In this scenario, COPD is a major cause of chronic morbidity and mortality, with substantial economic and social burdens [1,[7][8][9][10][11][12][13][14]. The discovery regarding the origin of chronic respiratory disease in the first years of life modified the classic concept of COPD as solely a "smoker's disease" [15,16].…”

Section: Introductionmentioning

confidence: 99%

Regenerative and translational medicine in COPD: hype and hope

Guarnier,

Moro,

Lívero

et al. 2023

Eur Respir Rev

View full text Add to dashboard Cite

COPD is a common, preventable and usually progressive disease associated with an enhanced chronic inflammatory response in the airways and lung, generally caused by exposure to noxious particles and gases. It is a treatable disease characterised by persistent respiratory symptoms and airflow limitation due to abnormalities in the airways and/or alveoli. COPD is currently the third leading cause of death worldwide, representing a serious public health problem and a high social and economic burden. Despite significant advances, effective clinical treatments have not yet been achieved. In this scenario, cell-based therapies have emerged as potentially promising therapeutic approaches. However, there are only a few published studies of cell-based therapies in human patients with COPD and a small number of ongoing clinical trials registered onclinicaltrials.gov. Despite the advances and interesting results, numerous doubts and questions remain about efficacy, mechanisms of action, culture conditions, doses, timing, route of administration and conditions related to homing and engraftment of the infused cells. This article presents the state of the art of cell-based therapy in COPD. Clinical trials that have already been completed and with published results are discussed in detail. We also discuss the questions that remain unanswered about cell-based regenerative and translational medicine for COPD.

show abstract

The Impact of the Age, Dyspnoea, and Airflow Obstruction (ADO) Index on the Medical Burden of Chronic Obstructive Pulmonary Disease (COPD)

Cited by 5 publications

References 33 publications

Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis

Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis

Comparison of BODE and ADO Indices in Predicting COPD-Related Medical Costs

Regenerative and translational medicine in COPD: hype and hope

Contact Info

Product

Resources

About